

'04年01月13日 (火) 14時40分 宛先: OBLON



発信: FUJISAWA PAT/TM

R: 914

P. 05

IN THE UNITED STATES  
PATENT AND TRADEMARK OFFICE

In re Application of:

KAZUHIKO TAKE ET AL.

Serial No.: 09/857,869

Art Unit 1624

Filed: June 12, 2001

EXAMINER: EMILY BERNHARDT

For: PIPERAZINE DERIVATIVES

DECLARATION

I, MASAHIKO MATSUO, a citizen of Japan residing at 4-56-7, Keyakidai, Sanda-shi, Hyogo, Japan, declare and say that:

I graduated from Kobe University, in March 1981 and completed the master course of Department of Science at Kobe University in March 1983;

Since April 1983, I have been as a pharmacologist, in the continuous employ of Fujisawa Pharmaceutical Co., Ltd., Osaka, Japan and now a senior manager of the Medicinal Biology Research Laboratories;

I received the Ph. D. Degree of Pharmacology, in 1997 from Osaka University;

I am a member of the Japanese Pharmacological Society; and





I received from Dr. Kazuhiko Take Test Compounds Example 5-(1), Example 14-(6), Example 14-(9) and Example 80-(3) and have measured their capability of h-NK<sub>1</sub> receptor binding.

The test result obtained is described in detail hereinafter.

Comparison between representative compounds of the present invention and the compound of Example 80-(3) in WO '954 as their capability of a h-NK1 receptor binding

Test method: the same as the test method described in the present application, pages 24-26

Test Results:

	Test Compounds	Capability of h-NK1 receptor binding IC <sub>50</sub>
Present application	Example 5-(1) 	$0.88 \times 10^{-9} \text{ M}$
	Example 14-(6) 	$0.72 \times 10^{-9} \text{ M}$
	Example 14-(9) 	$0.65 \times 10^{-9} \text{ M}$
WO '954	Example 80-(3) 	$2.14 \times 10^{-9} \text{ M}$

This result demonstrates that the binding capability

(affinity) of the representative compounds, Example 5-(1), Example 14-(6) and Example 14-(9) in the present invention is more than 2.4 to 3.3 times as strong as that of the compound of Example 80-(3) in WO '954.

It is declared by the undersigned that all statements made herein of undersigned's own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and that such willful false statements may jeopardize the validity of this application or any patent issuing thereon.

  
Masahiko Matsuo

This *13th* day of January, 2004  
Osaka, Japan

'04年01月13日(火) 14時40分 宛先: OBLON

発信: FUJISAWA PAT/TM

R:914

P.02



IN THE UNITED STATES  
PATENT AND TRADEMARK OFFICE

In re Application of:

KAZUHIKO TAKE ET AL.

Serial No.: 09/857,869

Art Unit 1624

Filed: June 12, 2001

EXAMINER: EMILY BERNHARDT

For: PIPERAZINE DERIVATIVES

DECLARATION

I, MASAHIKO MATSUO, a citizen of Japan residing at 4-56-7, Keyakidai, Sanda-shi, Hyogo, Japan, declare and say that:

I graduated from Kobe University, in March 1981 and completed the master course of Department of Science at Kobe University in March 1983;

Since April 1983, I have been as a pharmacologist, in the continuous employ of Fujisawa Pharmaceutical Co., Ltd., Osaka, Japan and now a senior manager of the Medicinal Biology Research Laboratories;

I received the Ph. D. Degree of Pharmacology, in 1997 from Osaka University;

I am a member of the Japanese Pharmacological Society; and





I received from Dr. Kazuhiko Take Test Compounds Example 5-(1), Example 14-(6), Example 14-(9) and Example 53-(1) and have measured their capability of h-NK<sub>1</sub> receptor binding.

The test result obtained is described in detail hereinafter.

Comparison between representative compounds of the present invention and the compound of Example 53-(1) in WO '597 as their capability of a h-NK1 receptor binding

Test method: the same as the test method described in the present application, pages 24-26

Test Results:

	Test Compounds	Capability of h-NK1 receptor binding IC <sub>50</sub>
Present application	Example 5-(1) 	$0.88 \times 10^{-9} \text{ M}$
	Example 14-(6) 	$0.72 \times 10^{-9} \text{ M}$
	Example 14-(9) 	$0.65 \times 10^{-9} \text{ M}$
WO '597	Example 53-(1) 	$6.20 \times 10^{-9} \text{ M}$

This result demonstrates that the binding capability

'04年01月13日(火)14時40分 宛先:OBLON

発信:FUJISAWA PAT/TM

R:914

P.04

(affinity) of the representative compounds, Example 5-(1), Example 14-(6) and Example 14-(9) in the present invention is more than 7 to 9 times as strong as that of the compound of Example 53-(1) in WO '597.

It is declared by the undersigned that all statements made herein of undersigned's own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and that such willful false statements may jeopardize the validity of this application or any patent issuing thereon.

  
Masahiko Matsuo

This *13<sup>th</sup>* day of January, 2004  
Osaka, Japan